Description

Cure CMD’s international research grants support work on congenital-onset laminopathies (L-CMD) and congenital-onset dystroglycanopathies (αDG). The program seeks research that explains disease mechanisms, identifies therapeutic targets, tests interventions, and advances promising approaches toward clinical application. Gene therapy, gene editing, gene modulation, disease models, biomarkers, and outcome measures are within scope.

For L-CMD, cardiac complications—including cardiomyopathy and conduction defects—are a particular priority, while skeletal muscle weakness and other consequences of LMNA mutations remain eligible topics. For αDG, Cure CMD strongly encourages research addressing cognitive and neural manifestations, alone or alongside muscle-directed approaches, and welcomes therapies with platform applicability across associated genes. Both categories aim to strengthen clinical trial readiness and translate research into treatments or improved care.